Comparison 3.
Resolution of ascites
| Outcome or subgroup title | No. of studies | No. of participants | Statistical method | Effect size |
|---|---|---|---|---|
| 1 All studies | 6 | 131 | Risk Ratio (M‐H, Fixed, 95% CI) | 0.91 [0.66, 1.27] |
| 2 Parenteral nutrition | 3 | 73 | Risk Ratio (M‐H, Fixed, 95% CI) | 0.71 [0.48, 1.05] |
| 2.1 Medical trials | 3 | 73 | Risk Ratio (M‐H, Fixed, 95% CI) | 0.71 [0.48, 1.05] |
| 2.2 Surgical trials | 0 | 0 | Risk Ratio (M‐H, Fixed, 95% CI) | 0.0 [0.0, 0.0] |
| 3 Enteral nutrition | 1 | 29 | Risk Ratio (M‐H, Fixed, 95% CI) | 0.86 [0.46, 1.62] |
| 3.1 Medical trials | 1 | 29 | Risk Ratio (M‐H, Fixed, 95% CI) | 0.86 [0.46, 1.62] |
| 3.2 Surgical trials | 0 | 0 | Risk Ratio (M‐H, Fixed, 95% CI) | 0.0 [0.0, 0.0] |
| 4 Supplements | 2 | 29 | Risk Ratio (M‐H, Fixed, 95% CI) | 4.16 [0.87, 19.84] |
| 4.1 Medical trials | 2 | 29 | Risk Ratio (M‐H, Fixed, 95% CI) | 4.16 [0.87, 19.84] |
| 4.2 Surgical trials | 0 | 0 | Risk Ratio (M‐H, Fixed, 95% CI) | 0.0 [0.0, 0.0] |
| 5 Medical trials | 6 | 131 | Risk Ratio (M‐H, Fixed, 95% CI) | 0.91 [0.66, 1.27] |
| 5.1 Parenteral nutrition | 3 | 73 | Risk Ratio (M‐H, Fixed, 95% CI) | 0.71 [0.48, 1.05] |
| 5.2 Enteral nutrition | 1 | 29 | Risk Ratio (M‐H, Fixed, 95% CI) | 0.86 [0.46, 1.62] |
| 5.3 Supplements | 2 | 29 | Risk Ratio (M‐H, Fixed, 95% CI) | 4.16 [0.87, 19.84] |
| 6 Surgical trials | 0 | 0 | Risk Ratio (M‐H, Fixed, 95% CI) | 0.0 [0.0, 0.0] |
| 6.1 Parenteral nutrition | 0 | 0 | Risk Ratio (M‐H, Fixed, 95% CI) | 0.0 [0.0, 0.0] |
| 6.2 Enteral nutrition | 0 | 0 | Risk Ratio (M‐H, Fixed, 95% CI) | 0.0 [0.0, 0.0] |
| 6.3 Supplements | 0 | 0 | Risk Ratio (M‐H, Fixed, 95% CI) | 0.0 [0.0, 0.0] |
| 7 Alcoholic hepatitis | 2 | 40 | Risk Ratio (M‐H, Fixed, 95% CI) | 1.01 [0.46, 2.19] |
| 7.1 Parenteral nutrition | 2 | 40 | Risk Ratio (M‐H, Fixed, 95% CI) | 1.01 [0.46, 2.19] |
| 7.2 Enteral nutrition | 0 | 0 | Risk Ratio (M‐H, Fixed, 95% CI) | 0.0 [0.0, 0.0] |
| 7.3 Supplements | 0 | 0 | Risk Ratio (M‐H, Fixed, 95% CI) | 0.0 [0.0, 0.0] |
| 8 Cirrhosis | 4 | 91 | Risk Ratio (M‐H, Fixed, 95% CI) | 0.89 [0.62, 1.27] |
| 8.1 Parenteral nutrition | 1 | 33 | Risk Ratio (M‐H, Fixed, 95% CI) | 0.57 [0.37, 0.88] |
| 8.2 Enteral nutrition | 1 | 29 | Risk Ratio (M‐H, Fixed, 95% CI) | 0.86 [0.46, 1.62] |
| 8.3 Supplements | 2 | 29 | Risk Ratio (M‐H, Fixed, 95% CI) | 4.16 [0.87, 19.84] |
| 9 HCC | 0 | 0 | Risk Ratio (M‐H, Fixed, 95% CI) | 0.0 [0.0, 0.0] |
| 9.1 Parenteral nutrition | 0 | 0 | Risk Ratio (M‐H, Fixed, 95% CI) | 0.0 [0.0, 0.0] |
| 9.2 Enteral nutrition | 0 | 0 | Risk Ratio (M‐H, Fixed, 95% CI) | 0.0 [0.0, 0.0] |
| 9.3 Supplements | 0 | 0 | Risk Ratio (M‐H, Fixed, 95% CI) | 0.0 [0.0, 0.0] |
| 10 Abstracts excluded | 6 | 131 | Risk Ratio (M‐H, Fixed, 95% CI) | 0.91 [0.66, 1.27] |
| 10.1 Parenteral nutrition ‐ medical trials | 3 | 73 | Risk Ratio (M‐H, Fixed, 95% CI) | 0.71 [0.48, 1.05] |
| 10.2 Parenteral nutrition ‐ surgical trials | 0 | 0 | Risk Ratio (M‐H, Fixed, 95% CI) | 0.0 [0.0, 0.0] |
| 10.3 Enteral nutrition ‐ medical trials | 1 | 29 | Risk Ratio (M‐H, Fixed, 95% CI) | 0.86 [0.46, 1.62] |
| 10.4 Enteral nutrition ‐ surgical trials | 0 | 0 | Risk Ratio (M‐H, Fixed, 95% CI) | 0.0 [0.0, 0.0] |
| 10.5 Supplements ‐ medical trials | 2 | 29 | Risk Ratio (M‐H, Fixed, 95% CI) | 4.16 [0.87, 19.84] |
| 10.6 Supplements ‐ surgical trials | 0 | 0 | Risk Ratio (M‐H, Fixed, 95% CI) | 0.0 [0.0, 0.0] |
| 11 Surgical trials without transplant | 0 | 0 | Risk Ratio (M‐H, Fixed, 95% CI) | 0.0 [0.0, 0.0] |
| 11.1 Parenteral nutrition | 0 | 0 | Risk Ratio (M‐H, Fixed, 95% CI) | 0.0 [0.0, 0.0] |
| 11.2 Enteral nutrition | 0 | 0 | Risk Ratio (M‐H, Fixed, 95% CI) | 0.0 [0.0, 0.0] |
| 11.3 Supplements | 0 | 0 | Risk Ratio (M‐H, Fixed, 95% CI) | 0.0 [0.0, 0.0] |
| 12 Intent to treat ‐ best‐case scenario for intervention ‐ no changes made because all patients with ascites reported | 6 | 131 | Risk Ratio (M‐H, Fixed, 95% CI) | 0.91 [0.66, 1.27] |
| 12.1 Parenteral nutrition ‐ medical trials | 3 | 73 | Risk Ratio (M‐H, Fixed, 95% CI) | 0.71 [0.48, 1.05] |
| 12.2 Parenteral nutrition ‐ surgical trials | 0 | 0 | Risk Ratio (M‐H, Fixed, 95% CI) | 0.0 [0.0, 0.0] |
| 12.3 Enteral nutrition ‐ medical trials | 1 | 29 | Risk Ratio (M‐H, Fixed, 95% CI) | 0.86 [0.46, 1.62] |
| 12.4 Enteral nutrition ‐ surgical trials | 0 | 0 | Risk Ratio (M‐H, Fixed, 95% CI) | 0.0 [0.0, 0.0] |
| 12.5 Supplements ‐ medical trials | 2 | 29 | Risk Ratio (M‐H, Fixed, 95% CI) | 4.16 [0.87, 19.84] |
| 12.6 Supplements ‐ surgical trials | 0 | 0 | Risk Ratio (M‐H, Fixed, 95% CI) | 0.0 [0.0, 0.0] |
| 13 Intent to treat ‐ worst case scenario for intervention ‐ no changes made because all patients with ascites reported | 6 | 131 | Risk Ratio (M‐H, Fixed, 95% CI) | 0.91 [0.66, 1.27] |
| 13.1 Parenteral nutrition ‐ medical trials | 3 | 73 | Risk Ratio (M‐H, Fixed, 95% CI) | 0.71 [0.48, 1.05] |
| 13.2 Parenteral nutrition ‐ surgical trials | 0 | 0 | Risk Ratio (M‐H, Fixed, 95% CI) | 0.0 [0.0, 0.0] |
| 13.3 Enteral nutrition ‐ medical trials | 1 | 29 | Risk Ratio (M‐H, Fixed, 95% CI) | 0.86 [0.46, 1.62] |
| 13.4 Enteral nutrition ‐ surgical trials | 0 | 0 | Risk Ratio (M‐H, Fixed, 95% CI) | 0.0 [0.0, 0.0] |
| 13.5 Supplements ‐ medical trials | 2 | 29 | Risk Ratio (M‐H, Fixed, 95% CI) | 4.16 [0.87, 19.84] |
| 13.6 Supplements ‐ surgical trials | 0 | 0 | Risk Ratio (M‐H, Fixed, 95% CI) | 0.0 [0.0, 0.0] |